Top Trades for Tomorrow: P, CMCSA, SNAP >>> READ MORE

3 Stocks to Watch on Friday: Cal-Maine Foods Inc (CALM), Cintas Corporation (CTAS) and OHR Pharmaceutical Inc (OHRP)

CALM stock was rising after the bell

By Karl Utermohlen, InvestorPlace Writer

The stock market experienced slight losses yesterday, with consumer discretionary stocks being the day’s duds, posting a 1% decline. The S&P 500 Index fell 0.2%, the Dow Jones Industrial Average declined 0.1% and the Nasdaq Composite slipped 0.4%.

3 Stocks to Watch on Friday: Cal-Maine Foods Inc (CALM), Cintas Corporation (CTAS) and OHR Pharmaceutical Inc (OHRP)Several companies posted their most recent earnings data Thursday afternoon, including Cal-Maine Foods Inc (NASDAQ:CALM), Cintas Corporation (NASDAQ:CTAS) and OHR Pharmaceutical Inc (NASDAQ:OHRP).

Here’s how they did:

Cal-Maine Foods Inc (CALM)

Cal-Maine Foods had decent quarterly data in its most recent period.

Over the course of the three-month period, earnings came in at 48 cents per share. Analysts were calling for earnings amounting to the same figure over the quarter.

As far as net sales go, Cal-Maine Foods managed to rake in $253.50 million, which was weaker than the $262.83 million that the consensus estimate called for.

However, the company posted a strong return on equity of 15.81%, while its net margin came in at 9.23%. Revenue was down 53% year-over-year, as the egg industry was to blame for the tough quarter.

There was a reduced demand for egg products over the three months.

The stock has an average consensus estimate of a “hold,” with a price target of $38.20.

CALM stock wafted up 1.31% after the bell yesterday.

Cintas Corporation (CTAS)

Cintas Corporation had a disappointing second quarter.

Yesterday, the company reported its fiscal second-quarter results which failed to meet expectations. Earnings came in at $140.4 million over, or about $1.29 per share.

On an adjusted basis, this figure was down to $1.15 per share. Analysts were calling for earnings of $1.16 per share, based on an average estimate of nine analysts.

Revenue managed to be higher than expected at $1.3 billion for the three-month period. Analysts were projecting revenue of $1.29 billion, according to six analysts surveyed by Zacks.

Full-year earnings are now slated to come in at around $4.51 to $4.59 per share, while revenue will be in the range of $5.18 billion to $5.23 billion.

CTAS shares lost 3.8% after hours Thursday.

OHR Pharmaceutical (OHRP)

OHR Pharmaceutical had a strong end of the year that helped shares rise higher.

The company revealed that its fiscal year 2016 was marked by progress in a number of drugs, including eye drop formulation Squalamine, as well as several other medications.

Overall, the year resulted in losses of $25.8 million, or 82 cents per share. The figure was wider than the 54 cents lost in the previous year.

OHR Pharmaceutical had cash and cash equivalents of $12.5 million by year’s end, which was about half of what it had in the previous year.

However, the company made progress in testing a number of drugs that have been costly. OHR Pharmaceutical expects to reap the rewards in the coming year, pending Food and Drug Administration approval.

OHRP stock soared 5.7% after the ring of the bell Thursday.

As of this writing, Karl Utermohlen did not hold a position in any of the aforementioned securities.

More From InvestorPlace

Article printed from InvestorPlace Media,

©2018 InvestorPlace Media, LLC